Related Experiment Video
Updated: Apr 5, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Predicting New Target Conditions for Drug Retesting Using Temporal Patterns in Clinical Trials: A Proof of Concept
1Department of Biomedical Informatics, Columbia University, New York, NY.
Abstract:
Drug discovery is costly and time-consuming. Efficient drug repurposing promises to accelerate drug discovery with reduced cost. However, most successful repurposing cases so far have been achieved by serendipity. There is a need for more efficient computational methods for predicting new indications for existing drugs. This paper conducts a retrospective analysis of the temporal patterns of drug intervention trials for every drug in a pair of different conditions in ClinicalTrials.gov, including 550 drugs used for 451 conditions between 2003 and 2013. We found that drugs are often targeted towards conditions that are related by similar or identical eligibility criteria. We demonstrated the preliminary feasibility of predicting new target conditions for drug retesting among conditions with similar aggregated clinical trial eligibility criteria and confirmed this hypothesis using evidence from the literature.
More Related Videos
03:08Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
Published on: October 3, 2025
05:28A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
Published on: August 27, 2019
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring: Drug Analysis Methods
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Drug Concentration Versus Time Correlation
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Pharmacogenomics: Identification of New Drug Targets
Pharmacokinetic–Pharmacodynamic Relationship: Problems